Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy ; volume:23 ; number:1 ; day:9 ; month:3 ; year:2023 ; pages:1-10 ; date:12.2023
BMC cancer ; 23, Heft 1 (9.3.2023), 1-10, 12.2023
- Urheber
-
Zhang, Yi
Kong, Fei-Fei
Zhu, Zheng-Qiu
Shan, Hai-Xia
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-10682-z
- URN
-
urn:nbn:de:101:1-2502250937382.545183109242
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Yi
- Kong, Fei-Fei
- Zhu, Zheng-Qiu
- Shan, Hai-Xia
- SpringerLink (Online service)
Ähnliche Objekte (12)
ASSESSMENT OF NUTRITIONAL STATUS OF PATIENTS RECEIVING CHEMOTHERAPY
Long-term virological outcome in children receiving first-line antiretroviral therapy
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
ASSESSMENT OF NUTRITIONAL STATUS OF PATIENTS RECEIVING CHEMOTHERAPY
Long-term virological outcome in children receiving first-line antiretroviral therapy
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
ASSESSMENT OF NUTRITIONAL STATUS OF PATIENTS RECEIVING CHEMOTHERAPY
Long-term virological outcome in children receiving first-line antiretroviral therapy
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations